ATE290014T1 - Festphasen-peptidsynthese - Google Patents

Festphasen-peptidsynthese

Info

Publication number
ATE290014T1
ATE290014T1 AT97939974T AT97939974T ATE290014T1 AT E290014 T1 ATE290014 T1 AT E290014T1 AT 97939974 T AT97939974 T AT 97939974T AT 97939974 T AT97939974 T AT 97939974T AT E290014 T1 ATE290014 T1 AT E290014T1
Authority
AT
Austria
Prior art keywords
peptide synthesis
phase peptide
solid phase
solid
relates
Prior art date
Application number
AT97939974T
Other languages
German (de)
English (en)
Inventor
Arne Holm
Bjarne Due Larsen
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Application granted granted Critical
Publication of ATE290014T1 publication Critical patent/ATE290014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)
AT97939974T 1996-09-09 1997-09-09 Festphasen-peptidsynthese ATE290014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK97196 1996-09-09
PCT/DK1997/000375 WO1998011125A1 (en) 1996-09-09 1997-09-09 Improved solid-phase peptide synthesis and agent for use in such synthesis

Publications (1)

Publication Number Publication Date
ATE290014T1 true ATE290014T1 (de) 2005-03-15

Family

ID=8099561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939974T ATE290014T1 (de) 1996-09-09 1997-09-09 Festphasen-peptidsynthese

Country Status (14)

Country Link
US (1) US7348404B2 (enExample)
EP (1) EP0929567B1 (enExample)
JP (1) JP4405594B2 (enExample)
AT (1) ATE290014T1 (enExample)
AU (1) AU723268B2 (enExample)
CA (1) CA2265900C (enExample)
CZ (1) CZ295838B6 (enExample)
DE (1) DE69732640T2 (enExample)
DK (1) DK0929567T3 (enExample)
ES (1) ES2239364T3 (enExample)
HU (1) HU230354B1 (enExample)
IL (1) IL128829A (enExample)
PT (1) PT929567E (enExample)
WO (1) WO1998011125A1 (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7550425B2 (en) 2000-06-16 2009-06-23 Zealand Pharma A/S Diuretic peptide conjugates
PT1737889E (pt) 2004-10-19 2010-12-13 Lonza Ag Método para síntese de péptidos em fase sólida
AU2006242998B2 (en) 2005-05-04 2012-03-22 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
GB0514071D0 (en) 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
US20090171097A1 (en) * 2005-11-22 2009-07-02 Hiroshi Sugiyama Automated solid phase synthesis of pyrrole-imidazole polyamide
PT1966130E (pt) 2005-12-23 2014-01-30 Zealand Pharma As Compostos miméticos de lisina modificados
EP1991560B1 (en) * 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
CN101437836B (zh) * 2006-03-29 2013-07-24 株式会社糖锁工学研究所 肽的硫酯化合物的制造方法
WO2008056155A1 (en) 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
HUE026255T2 (en) 2009-07-13 2016-06-28 Zealand Pharma As Acylated glucagon analogues
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
AP2013006671A0 (en) 2010-06-24 2013-01-31 Zealand Pharma As Glucagon analogues
SG192038A1 (en) 2011-01-20 2013-08-30 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
AU2012331053A1 (en) 2011-11-03 2014-05-29 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US20130316941A1 (en) 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
WO2013098408A1 (en) 2011-12-30 2013-07-04 Zealand Pharma A/S Glucagon and cck receptor agonist peptide conjugates
AR089860A1 (es) 2012-02-03 2014-09-24 Zealand Pharma As Analogos de la grelina
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP2844669B1 (en) 2012-05-03 2018-08-01 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
SG11201500375PA (en) 2012-07-23 2015-02-27 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CA2902432A1 (en) 2013-03-12 2014-10-09 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
US9695214B2 (en) 2013-03-15 2017-07-04 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
EP2976331B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of hydantoin containing peptide products
CA2907521C (en) 2013-03-21 2021-04-13 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
CN119119235A (zh) 2013-10-17 2024-12-13 西兰制药公司 酰化胰高血糖素类似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
ES2877356T3 (es) 2014-01-27 2021-11-16 Molecular Templates Inc Epítopo de MHC de clase I que suministra polipéptidos
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
DK3604333T3 (da) 2014-03-11 2021-06-21 Molecular Templates Inc Proteiner omfattende amino-terminale proksimale Shiga toksin A-underenhed-effektorregioner og cellemålrettede bindingsregioner af immunglobulin-typen, der er i stand til specifikt at binde CD38
AU2015274647C1 (en) 2014-06-11 2020-01-30 Molecular Templates, Inc. Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
US10479990B2 (en) 2014-06-26 2019-11-19 Ossianix, Inc. Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds
AU2015340586B2 (en) 2014-10-29 2020-04-30 Zealand Pharma A/S GIP agonist compounds and methods
WO2016077840A2 (en) 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
WO2016146739A1 (en) 2015-03-18 2016-09-22 Zealand Pharma A/S Amylin analogues
GB201506380D0 (en) 2015-04-15 2015-05-27 Serodus Asa Materials and methods for treatment of pulmonary hypertension
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
EP3325510A2 (en) 2015-07-26 2018-05-30 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN108290923A (zh) 2015-09-17 2018-07-17 麻省理工学院 用于固相肽合成的方法和系统
US11097010B2 (en) 2016-08-06 2021-08-24 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018104560A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
WO2018229252A1 (en) 2017-06-16 2018-12-20 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
WO2019089395A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
SG11202008177WA (en) 2018-02-27 2020-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
WO2019204272A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
US12258414B2 (en) 2018-06-22 2025-03-25 Ossianix, Inc. Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
EP3914610A1 (en) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
CN113710324B (zh) 2019-01-23 2025-02-14 千禧制药公司 抗cd38抗体
CA3138715A1 (en) 2019-06-14 2020-12-17 Zealand Pharma A/S Pharmaceutical parenteral composition of dual glp1/2 agonist
CA3148536A1 (en) 2019-08-27 2021-03-04 Anne Pernille Tofteng SHELTON Compstatin analogues and their medical uses
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
NZ786148A (en) 2019-09-20 2025-09-26 Zealand Pharma As Kv1.3 blockers
US20210155671A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
EP4126003A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
MX2023000679A (es) 2020-07-16 2023-04-18 Zp Spv 3 K/S Inhibidores del factor c3 del complemento y sus usos medicos.
WO2022103769A1 (en) 2020-11-11 2022-05-19 Ossianix, Inc. High affinity human and monkey specific tfr-1 vnars
JP7751641B2 (ja) 2020-12-16 2025-10-08 ジーランド ファーマ エー／エス Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
CA3196989A1 (en) 2020-12-16 2022-06-23 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
US20240024425A1 (en) 2020-12-16 2024-01-25 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
WO2022175410A1 (en) 2021-02-18 2022-08-25 Zealand Pharma A/S Composition for treating short bowel syndrome
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
AU2022245193A1 (en) 2021-03-23 2023-09-07 Zealand Pharma A/S Kv1.3 blockers
WO2022260877A1 (en) 2021-06-07 2022-12-15 Ossianix, Inc. Shark vnars for treating covid-19
US20240279298A1 (en) 2021-06-18 2024-08-22 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Glucagon analog and medical use thereof
AU2022329980A1 (en) 2021-08-17 2024-02-15 Ossianix, Inc. Deimmunized vnar domains and scaffolds
TW202315882A (zh) 2021-09-03 2023-04-16 丹麥商西蘭製藥公司 給藥方案
EP4440592A1 (en) 2021-12-01 2024-10-09 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4593864A1 (en) 2022-09-28 2025-08-06 Zealand Pharma A/S Methods for treating obesity
CA3267935A1 (en) 2022-10-18 2024-04-25 Zealand Pharma A/S INHIBITORS
WO2024168411A1 (pt) * 2023-02-15 2024-08-22 Proteimax Bio Technology Israel Ltd Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism
TW202528338A (zh) 2023-12-04 2025-07-16 丹麥商西蘭製藥公司 方法
TW202530247A (zh) 2023-12-04 2025-08-01 丹麥商西蘭製藥公司 方法
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
US20250381242A1 (en) 2024-06-12 2025-12-18 Invaio Sciences, Inc. Antimicrobial peptides against citrus greening
US20250382332A1 (en) 2024-06-12 2025-12-18 Invaio Sciences, Inc. Novel alpha-factor based peptides with antifungal activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116666A (enExample) 1974-07-30 1976-02-10 Shionogi Seiyaku Kk
US5021550A (en) * 1986-10-07 1991-06-04 Thomas Jefferson University Method for preventing deletion sequences in solid phase synthesis
JP2807287B2 (ja) 1989-10-13 1998-10-08 株式会社医学生物学研究所 ペプチドおよびその用途
EP0719334A1 (en) 1993-09-14 1996-07-03 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
US7176282B1 (en) 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

Also Published As

Publication number Publication date
DE69732640D1 (de) 2005-04-07
HU230354B1 (hu) 2016-02-29
CA2265900A1 (en) 1998-03-19
AU723268B2 (en) 2000-08-24
JP2001500134A (ja) 2001-01-09
JP4405594B2 (ja) 2010-01-27
AU4199397A (en) 1998-04-02
EP0929567A1 (en) 1999-07-21
HUP0102900A2 (hu) 2002-01-28
DK0929567T3 (da) 2005-06-27
WO1998011125A1 (en) 1998-03-19
CZ80399A3 (cs) 1999-08-11
ES2239364T3 (es) 2005-09-16
DE69732640T2 (de) 2006-01-12
US20070004905A1 (en) 2007-01-04
CA2265900C (en) 2007-07-31
US7348404B2 (en) 2008-03-25
PT929567E (pt) 2005-07-29
IL128829A0 (en) 2000-01-31
EP0929567B1 (en) 2005-03-02
CZ295838B6 (cs) 2005-11-16
HUP0102900A3 (en) 2002-02-28
IL128829A (en) 2005-08-31

Similar Documents

Publication Publication Date Title
ATE290014T1 (de) Festphasen-peptidsynthese
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
TR200001985T2 (tr) Kapa reseptörü opioid peptidleri.
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
ATE233277T1 (de) Cyklische peptide, die an den urokinase-type plasminogen aktivator rezeptor binden
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
DZ3482A1 (fr) Secretagogues de l'hormone de croissance
TR200000930T2 (tr) Büyüme hormonu sekretagogları.
ATE394482T1 (de) Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
SE9903291D0 (sv) New process
AU580350B2 (en) Process for synthesising peptides
FI953525L (fi) Kemiallinen syntetointimenetelmä fibronektiiniä sitovan proteiinin tai polypeptidin valmistamiseksi
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
HUT55800A (en) Process for producing anticoagulant peptides
ATE173022T1 (de) Produktion von peptid-amiden
EP1123108A4 (en) ISOLATED PEPTIDES ATTACHING TO HLA-B35 MOLECULES
GR3021660T3 (en) Anticoagulant peptides
SE9800865D0 (sv) New Process
SE9604439D0 (sv) New receptor
IT1264598B1 (it) Intermedi per la preparazione di peptidi retro-inversi
IT1270613B (it) Lattami biciclici come intermedi per la sintesi di peptidi biologicamente attivi
ATE417105T1 (de) Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0929567

Country of ref document: EP